文献速递浆细胞疾病

同时给予地塞米松的给药方案对硼替佐米诱导的多发性骨髓瘤周围神经病变的影响

Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma.
PubMed 文献 · Br J Haematol · 2017-06-07

该回顾性分析纳入32项研究(2697例初治多发性骨髓瘤患者),比较硼替佐米联合不同地塞米松给药方案下的周围神经病变(PN)发生率。伙伴给药、每周给药和其他给药方案的汇总总体PN率分别为45.5%、63.9%和47.5%,≥3级PN率分别为5.3%、11.0%和9.6%。校正潜在混杂因素后,伙伴给药方案的PN率似乎低于每周或其他给药方案。

要点

  • 伙伴地塞米松给药方案汇总总体PN率为45.5%,≥3级PN率为5.3%。
  • 每周地塞米松给药方案汇总总体PN率为63.9%,≥3级PN率为11.0%。
  • 其他地塞米松给药方案汇总总体PN率为47.5%,≥3级PN率为9.6%。

核心结论

  • 这些发现提示,与替代地塞米松给药方案相比,伙伴地塞米松给药方案可能导致较不严重的硼替佐米诱导的PN。

研究设计与样本

  • 回顾性分析32项研究,纳入2697例既往未治疗的多发性骨髓瘤患者,这些研究包含硼替佐米且地塞米松给药方案不同。

主要发现

  • 伙伴给药、每周给药和其他给药方案的汇总总体PN率分别为45.5%、63.9%和47.5%,≥3级PN率分别为5.3%、11.0%和9.6%。
  • 校正潜在混杂因素(年龄、性别、是否联用沙利度胺、硼替佐米治疗持续时间)后,伙伴给药方案患者的PN率似乎低于每周或其他给药方案患者。
  • 使用患者水平数据的分析提示,累积地塞米松剂量这一潜在混杂因素不太可能影响分析结果。
  • 排除含沙利度胺方案数据的单独汇总分析结果相似,伙伴给药、每周给药和其他给药方案的汇总总体PN率分别为50.1%、63.9%和48.3%,≥3级PN率分别为4.2%、11.0%和8.6%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Peripheral neuropathy (PN) is the most troublesome adverse event associated with the proteasome inhibitor bortezomib. Studies suggest an inflammatory aetiology for bortezomib-induced PN (BiPN) and it has been hypothesized that reducing inflammation with concomitant dexamethasone may reduce BiPN incidence and/or severity. We retrospectively analysed PN rates from 32 studies (2697 patients with previously untreated multiple myeloma) incorporating bortezomib and differing dexamethasone schedules: partnered dosing (days of and after bortezomib), weekly dosing, and other dosing schedules (e.g. days 1-4, 8-11). Pooled overall PN rates were 45·5%, 63·9%, and 47·5%, respectively, with 5·3%, 11·0%, and 9·6% grade ≥3. Adjusting for potential confounders (age, gender, presence of thalidomide, bortezomib treatment duration), PN rates in patients on partnered dosing schedules appeared lower than in patients on weekly or other dosing schedules. Analyses conducted using patient-level data suggest that cumulative dexamethasone dose, a potential confounding factor, is unlikely to have influenced the analyses. Findings were similar in a separate pooled analysis excluding data from regimens incorporating thalidomide, when pooled overall PN rates were 50·1%, 63·9%, and 48·3%, respectively, with 4·2%, 11·0%, and 8·6% grade ≥3. These findings suggest that partnered dexamethasone dosing may result in less severe BiPN compared with alternative dexamethasone dosing schedules.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Kumar SK, Laubach JP, Giove TJ, et al. Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma. Br J Haematol. 2017. PMID: 28591409. doi:10.1111/bjh.14754

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。